Abstract
Granulocyte colony stimulating factor (G-CSF) [1] and granulocyte macrophage CSF (GMCSF) [2] were first given after chemotherapy to patients with relapsed or refractory acute leukemia [1] and patients with AML at higher age or after relapse [2]. The growth factors significantly (by 1 week) reduced the neutrophil recovery time [1,2], early mortality [2] and incidence of documented infections [1]. Leukemic regrowth was not observed [1] or rare and then GM-CSF independent or reversible [2, 3]. Remission duration - now projected to 3 years - is equal to that in the controls [4].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Ohno R, Tomonaga M, Kobayashi T et al. (1990) Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. New Engl J Med 323: 871–877
Büchner T, Hiddemann W, Koenigsmann M et al. (1991) Recombinant human granulocytemacrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse. Blood 78: 1190–1197
Koenigsmann M, Hiddemann W, Büchner T (1991) Reversible leukaemic regrowth under GM-CSF treatment after chemotherapy for AML. Leuk Res 15: 37–41
Büchner T, Hiddemann W, Wörmann B et al. (1992) Long-term results after chemotherapy (CT) followed by GM-CSF in patients with high risk AML. Proceedings of ASCO 11: 852
Bettelheim P, Valent P, Andreeff M et al. (1991) Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. Blood 77: 700–711
Estey E, Thall PF, Kantarjian H et al. (1992) Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colonystimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF. Blood 79: 2246–2255
Koistinen P, Wang C, Curtis JE, McCulloch EA (1991) Granulocyte-macrophage colony-stimulating factor and interleukin-3 protect leukemic blast cells from Ara-C toxicity. Leukemia 5: 789–795
Van der Lely N, De Witte T, Muus P et al. (1991) Prolonged exposure to cytosine arabinoside in the presence of hematopoietic growth factors preferentially kills leukemic versus normal clonogenic cells. Exp Hematol 19: 267–272
Bhalla K, Birkhofer M, Arlin Z et al. (1991) Differential effect of interleukin 3 on the metabolism of high-dose cytosine arabinoside in normal versus leukemic human bone marrow cells. Exp Hematol 19: 669–673
Bhalla K, Holladay C, Arlin Z et al. (1991) Treatment with interleukin-3 plus granulocytemacrophage colony-stimulating factor improves the selectivity of Ara-C in vitro against acute myeloid leukemia blasts. Blood 78: 2674–2679
Büchner T, Urbanitz D, Hiddemann W et al. (1985) Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. J Clin Oncol 12: 1583–1589
Büchner T, Hiddemann W, Lömer G et al. (1991) Improved cure rate by very early intensification combined with prolonged maintenance chemotherapy in patients with acute myeloid leukemia: Data from the AML Cooperative Group. Sem Hematol 28: 76–79
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Büchner, T. et al. (1994). GM-CSF in Chemotherapy for Newly Diagnosed AML: Multiple Course Priming and Longterm Administration Compared to Chemotherapy Alone. In: Büchner, T., Hiddemann, W., Wörmann, B., Schellong, G., Ritter, J. (eds) Acute Leukemias IV. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 36. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-78350-0_25
Download citation
DOI: https://doi.org/10.1007/978-3-642-78350-0_25
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-78352-4
Online ISBN: 978-3-642-78350-0
eBook Packages: Springer Book Archive